{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tanaka Y"],"funding":["Japan Agency for Medical Research and Development"],"pagination":["e004701"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11409405"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(3)"],"pubmed_abstract":["Objectives
To evaluate the safety, tolerability, pharmacokinetics (PK), biomarker response and efficacy of E6742 in a phase I/II study in patients with systemic lupus erythematosus (SLE).Methods
Two sequential cohorts of patients with SLE were enrolled and randomised to 12 weeks of two times per day treatment with E6742 (100 or 200 mg; n=8 or 9) or placebo (n=9). The primary endpoint was safety, the secondary endpoints were PK and interferon gene signature (IGS), and the exploratory endpoints were efficacy and biomarker.Results
The proportion of patients with any treatment-emergent adverse events (TEAEs) was 58.8% in the E6742 group (37.5% (3/8 patients) for 100 mg; 77.8% (7/9 patients) for 200 mg) and 66.7% (6/9 patients) in the placebo group. No Common Terminology"],"journal":["RMD open"],"pubmed_title":["Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus."],"pmcid":["PMC11409405"],"funding_grant_id":["JP19pc0101038"],"pubmed_authors":["Aoki M","Tanaka Y","Atsumi T","Tago F","Akira S","Ishii T","Yamamuro S","Kumanogoh A"],"additional_accession":[]},"is_claimable":false,"name":"Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus.","description":"Objectives
To evaluate the safety, tolerability, pharmacokinetics (PK), biomarker response and efficacy of E6742 in a phase I/II study in patients with systemic lupus erythematosus (SLE).Methods
Two sequential cohorts of patients with SLE were enrolled and randomised to 12 weeks of two times per day treatment with E6742 (100 or 200 mg; n=8 or 9) or placebo (n=9). The primary endpoint was safety, the secondary endpoints were PK and interferon gene signature (IGS), and the exploratory endpoints were efficacy and biomarker.Results
The proportion of patients with any treatment-emergent adverse events (TEAEs) was 58.8% in the E6742 group (37.5% (3/8 patients) for 100 mg; 77.8% (7/9 patients) for 200 mg) and 66.7% (6/9 patients) in the placebo group. No Common Terminology","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-06-01T10:03:35.707Z","creation":"2025-04-04T08:22:00.99Z"},"accession":"S-EPMC11409405","cross_references":{"pubmed":["39289029"],"doi":["10.1136/rmdopen-2024-004701"]}}